No summons during grace period for medicine price display, says MOH
Health deputy director-general (Pharmaceutical Services) Dr Azuana Ramli said the Price Control and Anti-Profiteering (Price Labelling for Medicines) Order 2025, which came into force on May 1, would initially focus on educational aspects to ensure all stakeholders understand the new requirements.
'During these three months, there are no plans to issue any summons. This phase is focused on advocacy and monitoring how the implementation is being carried out,' she said at a briefing session on the Medicine Price Display initiative here today.
Also present was Domestic Trade and Cost of Living Ministry (KPDN) Enforcement director-general Datuk Azman Adam.
Under the order, all private healthcare facilities and community pharmacies must display clear price labels for medicines, either on shelves, in catalogues or in written price lists.
Azuana said that during these three months, monitoring would be led by the MOH's Pharmaceutical Services Division, supported by KPDN enforcement officers.
Asked whether the initiative constitutes price control, she clarified that it aims to enhance price transparency under the Price Control and Anti-Profiteering Act 2011, and not about controlling medicine prices.
Meanwhile, Azman refuted claims by a private doctors' group that KPDN officers issued three-day warning notices to clinics yesterday.
He explained that the enforcement team was in the area for inspections related to cooking gas and egg supplies, and happened to ask a clinic staff member about the implementation of the price display rule.
'No notices or summonses were issued,' he said.
Asked about the possibility of price manipulation in response to the regulation, Azman expressed confidence in the industry's maturity.
The medicine price display initiative aims to enhance price transparency, protect consumer and patient rights, improve the quality of healthcare services, promote healthy industry competition, and support informed decision-making by consumers. — BERNAMA
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
4 hours ago
- New Straits Times
Exco: MOH health personnel deployed to Pasir Gudang Hospital
PASIR GUDANG: Pasir Gudang Hospital (HPG) is now receiving health personnel from various locations nationwide, deployed by the Health Ministry (MOH) as part of early preparations for its opening. Johor Health and Environment Committee chairman Ling Tian Soon said the personnel had been assigned according to the needs of their respective departments, with task distribution also carried out to ensure smooth operations when the hospital begins service. "Although Pasir Gudang Hospital has announced a postponement of its opening date, preparation work has never stopped. "Various medical and non-medical equipment have begun arriving at the hospital, and the hospital staff are busy arranging and registering them," he said in a Facebook post yesterday. On Aug 4, he was reported as saying that the opening of HPG here, initially scheduled to begin operations in stages on Aug 1, had been postponed to next year due to several technical issues, including a shortage of health personnel, particularly doctors and nurses. He said the decision was also agreed upon by the MOH and the state government to avoid any problems arising from the shortage of staff. – BERNAMA
Barnama
15 hours ago
- Barnama
MBSB IB Maintains Positive Call On Insurance Sector Despite Healthcare Inflation
-- Photograph for illustrative purposes MBSB IB Maintains Positive Call On Insurance Sector Despite Healthcare Inflation KUALA LUMPUR, Aug 15 (Bernama) -- MBSB Investment Bank (MBSB IB) has maintained its 'positive' recommendation on the insurance sector, citing attractive valuations and high dividend yields despite persistent healthcare inflation and delays in healthcare cost-control reforms. In a research note today, the bank said healthcare inflation remains a 'tricky issue to fix' as higher spending on the sector appears inevitable. 'Our primary concern is that if healthcare inflation is still rampant, what will happen at the end of Bank Negara Malaysia's three-year cap on medical insurance premium hikes? 'But there are multiple tailwinds -- a cheap price point, attractive dividend yields, a potential windfall in investment income, and encouraging progress by insurers in addressing the healthcare inflation problem -- making the sector due for a positive re-rating,' it said. The bank noted that companies under its coverage are market leaders, enabling them to withstand challenges better than most. MBSB IB said medical cost pressures are being fuelled by private hospitals rejecting proposed cost freezes, opposing pharmaceutical price controls, and what insurers describe as 'buffet table syndrome', where high claims are linked to increased service use without clear medical need. It also pointed to Malaysia's relatively low preventive healthcare spending and intensifying competition in healthcare tourism from Thailand, Indonesia and Singapore. However, the bank highlighted some progress in tackling medical inflation, including the Price Control and Anti-Profiteering (Price Marking for Drug) Order 2025, which will require mandatory medicine price displays in the private sector by 2026. 'The initiative aims to enable the public to make informed choices by knowing the prices in advance and to encourage competitive medical pricing, although it has faced resistance, with several medical groups filing a judicial review," it said. The bank added that another factor is the decline in active pharmaceutical ingredient (API) raw material prices to pre-pandemic levels, after surging during the pandemic and staying elevated for several years due to logistical constraints, factory closures and increased demand for healthcare products. MBSB IB's top picks are Allianz Malaysia Bhd, with a target price of RM21.59, and Syarikat Takaful Malaysia Keluarga Bhd, with a target price of RM4.59, while LPI Capital Bhd is also rated 'buy'. -- BERNAMA
BusinessToday
16 hours ago
- BusinessToday
Insurance Sector Poised For Healthy Gain Despite Inflation Worries
MBSB Investment Bank Bhd (MBSB Research) has maintained a POSITIVE call on the insurance sector, citing attractive valuations, solid dividend yields, and signs of progress in tackling healthcare inflation despite persistent headwinds. Allianz and Syarikat Takaful Malaysia Bhd (STMB) remain top picks with 'buy' recommendations and target prices of RM21.59 and RM4.59, respectively. The optimism comes even as the government once again postponed the mandatory rollout of the diagnosis-related groups (DRG) payment system for private hospitals, pushing the implementation from mid-2025 to 2027. The DRG framework, widely used in countries such as Thailand and Indonesia, aims to standardise hospital reimbursement based on diagnosis and treatment rather than charging per service. An interim version will begin in selected private hospitals this year, alongside a basic Medical and Health Takaful Insurance platform scheduled for 2026. Insurers have been taking firmer steps to address medical cost inflation, though MBSB noted that increased healthcare spending remains unavoidable. Malaysia's healthcare tourism industry is under competitive pressure from regional players such as Thailand and Singapore, with private hospitals investing heavily in high-end facilities to attract overseas patients. The Association of Private Hospitals Malaysia (APHM) has pushed back against several insurer proposals, including freezing private hospital costs for three years and regulating pharmaceutical prices, arguing these could compromise care standards and limit access to new treatments. Rising claims have also been attributed by APHM to more severe patient cases, potentially linked to post-pandemic complications. Preventive care remains a weak spot, with just 6–7% of the Health Ministry's budget allocated to prevention, far below the treatment allocation. Still, MBSB highlighted recent progress. The Price Control and Anti-Profiteering Order 2025 will require private sector medicine price displays by 2026, promoting transparency and competition. The cost of active pharmaceutical ingredients has also retreated to pre-pandemic levels, easing some pressure on drug prices. Furthermore, co-pay uptake is gaining traction, with Allianz reporting encouraging adoption rates and insurers seeing lower health loss ratios in early 2025. MBSB Research emphasised that while healthcare inflation is unlikely to disappear, continued insurer initiatives, combined with a low sector price point and the potential for higher investment income, provide a case for a positive re-rating. The firm noted that companies under its coverage are market leaders, better positioned to navigate economic uncertainty and the structural challenges of rising reinsurance costs. However, risks remain, including the possibility of slower premium growth if the economy weakens and the threat of persistent healthcare inflation even after the DRG rollout.
